Nemophila menziesii

Botanical Identity and Nomenclature

Nemophila menziesii Hook. & Arn. is the accepted botanical name for the annual herb commonly known as baby blue eyes or baby's-blue-eyes. The full scientific authority reads Nemophila menziesii Hook. et Arn. (Boraginaceae), and the plant is an annual herb primarily used for ornamental purposes. It belongs to the kingdom Plantae, order Boraginales, family Boraginaceae; this placement reflects modern phylogenetic classification of the Boraginales, where the former family Hydrophyllaceae has been subsumed into Boraginaceae. Within Boraginaceae, the genus Nemophila is situated in the subfamily Hydrophylloideae, which also encompasses related genera such as Hydrophyllum.

The genus name derives from the Greek words nemos, meaning wooded pasture or glade, and phileo, meaning to love, in reference to the preferred habitat of several species. The specific epithet menziesii honors Archibald Menzies (1754–1842), a Scottish botanist, plant collector, and surgeon who accompanied George Vancouver aboard HMS Discovery in a world voyage in the 1790s that explored, in part, the Pacific Northwest.

The species is divided into three botanical varieties based on morphological differences, including flower color and leaf dissection: var. menziesii, var. atomaria, and var. integrifolia. The variety atomaria has white flowers with black dots, often with a faint blue tint or blue veins in the corolla. Historically, the nomenclatural synonyms include Nemophila menziesii subsp. insignis (Benth.) Brand and several other infraspecific taxa documented in older monographic treatments.

Natural Source and Botanical Description

Nemophila menziesii is an annual herb native to western North America. The plant is native to California, Baja California, and Oregon; it grows virtually throughout California at elevations from sea level up to almost 6,500 feet (2,000 m) and in many types of habitats, including chaparral, valley grasslands, and montane locales.

The plant is a low-growing annual herbaceous species in the Boraginaceae family, characterized by fleshy stems reaching 8–12 inches (20–30 cm) in height, small gray-green pinnately lobed leaves, and saucer-shaped bright blue flowers measuring about 1.5 inches (3.8 cm) across with white or light blue centers and darker spots. Lower leaves are stalked, lobed, and oppositely arranged, 10–50 millimetres in length with five to thirteen lobes; upper leaves are more or less sessile and less lobed than lower ones. The flower is blue with a white center or all white, usually with blue veins and black dots near the center.

In areas with hot, humid summer climates, plants typically bloom from spring until June, when they decline rapidly and die with the onset of consistently high heat and humidity. Baby blue eyes is a member of the borage family and counts Phacelias among its relatives.

Forms and Preparations

Nemophila menziesii is an annual herb often used for ornamental purposes; although native to North America, the blue flowers of the cultivar "Insignis Blue" are popular in gardens and parks worldwide. The plant is not commonly used for medicinal or culinary purposes despite several reports regarding the presence of a blue flower pigment.

In research settings, the plant has been processed as a whole-plant acetone–water (4:1) extract for phytochemical isolation. The acetone–water extract of the whole plants of Nemophila menziesii Hook. et Arn. was subjected to column chromatography to yield approximately separated fractions using a methanol–water mobile phase solvent system. There are no established standardized dietary supplement formulations, recognized pharmacopeial monographs, or approved medicinal preparations of N. menziesii documented in authoritative sources at the time of writing. The plant is not listed in major regulatory frameworks such as NIH Office of Dietary Supplements databases, WHO monographs, ESCOP, the German Commission E, or the European Pharmacopoeia as a recognized supplement ingredient.

Traditional and Historical Use

Documented ethnobotanical uses of Nemophila menziesii are extremely sparse in the peer-reviewed literature. Historically, the plant was eaten by cows kept by the Kawaiisu — a Native American people of the Tehachapi Mountain region of California — representing one of the few specific recorded interactions between an indigenous group and this species, though this describes livestock forage rather than human medicinal use.

No primary ethnobotanical monographs or peer-reviewed ethnobotanical surveys document human medicinal or culinary preparations of N. menziesii specifically. Nemophila menziesii is not commonly used for medicinal or culinary purposes. Claims that appear on commercial wellness and supplement-brand websites purporting Native American medicinal traditions of teas, poultices, or use as a calming agent for N. menziesii specifically are not corroborated by primary ethnobotanical sources and should be treated with considerable skepticism.

The broader family Boraginaceae has a long tradition of use in various healing systems. Research on Boraginaceae taxa has confirmed their use in traditional medicine and proved the potential biological importance of various molecules in cosmetology. However, the established traditional uses within this family — such as the use of Symphytum (comfrey) or Borago (borage) — are not transferable to N. menziesii without direct documentation, and no such documentation exists in authoritative sources for this species.

Key Constituents and Active Compounds

Metalloanthocyanin: Nemophilin

A novel metalloanthocyanin, nemophilin, was found in the blue petals of Nemophila menziesii. The brilliant blue color of the Nemophila menziesii flower is derived from metalloanthocyanin, which consists of anthocyanin — specifically petunidin 3-O-[6-O-(trans-p-coumaroyl)-β-glucoside]-5-O-[6-O-(malonyl)-β-glucoside] — flavone [apigenin 7-O-β-glucoside-4'-O-(6-O-malonyl)-O-β-glucoside], and metal ions (Mg²⁺ and Fe³⁺).

Reconstruction experiments using the anthocyanin and flavone components with various combinations of metal ions showed that they with magnesium ions yield a purplish-blue-colored metalloanthocyanin (Mg–Mg nemophilin), while both magnesium and iron ions together generate a blue metalloanthocyanin (Fe–Mg nemophilin). Nemophilin is the first metalloanthocyanin with an anthocyanin component of a petunidin chromophore. Both Mg–Mg- and Mg–Fe-type complexes coexist in the petals; in previously reported metalloanthocyanins, only one pigment — such as commelinin, protocyanin, protodelphin, or cyanosalvianin — was contained in the petals.

The metalloanthocyanin complex nemophilin is one of only a small number of such supramolecular pigment complexes known in the plant kingdom. Some plants — including Commelina communis, Centaurea cyanus, Salvia patens, Salvia uliginosa, and Nemophila menziesii — develop a pure blue color by accumulating metalloanthocyanin complexes. Violet/blue flowers tend to contain delphinidin-based anthocyanins, which are often modified with multiple glycosyl and aromatic acyl moieties; the presence of co-pigments, typically glucosides of flavones and flavonols, causes a bathochromic shift in the anthocyanins by intramolecular stacking to yield darker, bluer hues.

Flavone Glucosyltransferases and Biosynthetic Pathway

The blue flower color of Nemophila menziesii is derived from nemophilin, which comprises petunidin-3-O-[6-O-(trans-p-coumaroyl)-β-glucoside]-5-O-[6-O-(malonyl)-β-glucoside], apigenin-7-O-β-glucoside-4′-O-(6-O-malonyl)-β-glucoside, and Mg²⁺ and Fe³⁺ ions; the flavonoid biosynthetic pathway of nemophilin had not been characterized at the time of early studies. RNA-Seq analysis of the petals yielded 61,491 contigs. Spatio-temporal transcriptome analysis indicated that genes involved in the early part of the pathway are strongly expressed during early-petal development and those in the late part at late-flower opening stages, but they are rarely expressed in leaves.

A 2018 study published in Plant and Cell Physiology characterized two glucosyltransferase (GT) enzymes from N. menziesii. Two GT cDNAs, NmF4'GT and NmF4'G7GT, which are highly expressed during the early stages of petal development and rarely in leaves, were shown to encode F4'GT and F4'G7GT activities, respectively. These enzymes catalyze key steps in the biosynthesis of the flavone co-pigment (apigenin 7,4'-O-diglucoside) that forms an essential component of nemophilin.

Meroterpenoid Glucosides: Nemophilosides A–I

The most significant phytochemical discovery regarding N. menziesii as a source of potentially bioactive compounds came from a 2025 study (Kurosawa et al., published in the Journal of Natural Medicines and indexed on PubMed Central, PMC12847176). Nine previously undescribed meroterpenoid glucosides, named nemophilosides A–I, were isolated from the whole plant extract of Nemophila menziesii; their molecular structures were determined from NMR and MS spectra, and absolute configurations were confirmed using ECD spectroscopy by comparing experimental data with calculated data.

The meroterpenoids consist of monoterpenoids and hydroquinone moieties; meroterpenoids obtained as glycosides are relatively rare, which distinguishes this class of compounds. Their skeletons are similar to those of cannabinoids and shikonins, suggesting homologous biosynthetic pathways. Compared with well-known meroterpenoids, the monoterpenoid moieties of the compounds isolated in this study were characterized by oxidation.

Meroterpenoids are complexes of terpenoids and other biosynthetic products isolated from plants, fungi, and marine products, and exhibit diverse and potent biological activities; they are expected to show potential as pharmaceutical seeds. The family Boraginaceae is recognized as one of the plant families that biosynthesize quinone-type meroterpenoids, with many characteristic meroterpenoids identified from the genera Lithospermum, Cordia, and Arnebia. In this study, significant meroterpenoids with quinone moiety were isolated from the whole plant of N. menziesii (Insignis Blue); notably, the meroterpenoids were isolated as glucoside types on the quinone.

Other Flavonoid Constituents

In addition to the metalloanthocyanin nemophilin and the meroterpenoid glucosides, the petals and broader plant tissue of N. menziesii contain a range of flavonoid compounds used in biochemical research. These include apigenin and its glycosides (apigenin 7-glucoside, apigenin 4'-glucoside, apigenin 7,4'-diglucoside), luteolin and its glucosides (luteolin 7-glucoside, luteolin 4'-glucoside), kaempferol glycosides, and quercetin glycosides, as referenced in laboratory compound panels used to characterize the glucosyltransferase enzymes. The broader Boraginaceae family is also associated with fatty acids including γ-linolenic acid, essential oils, phenolic acids such as rosmarinic acid, flavonoids, anthocyanins, tannins, saponins, and highly specific naphthoquinone pigments including shikonin and allantoin. Whether all these compound classes are present in meaningful quantities in N. menziesii specifically has not been confirmed by targeted phytochemical studies beyond the meroterpenoids and anthocyanin pigments described above.

Mechanisms of Action

Nitric Oxide Modulation (In Vitro)

The only experimentally investigated mechanism of action attributable to an isolated compound from N. menziesii as of 2025 relates to nitric oxide (NO) regulation. Although the nemophilosides (A–I) showed little or no inhibitory activity against fatty acid amide hydrolase and acetylcholinesterase, compound 6 regulated NO production in RAW264.7 cells.

More specifically, compound 6 significantly regulated nitric oxide (NO) production from LPS-stimulated RAW264.7 cells at 100 µg/mL with no toxicity, showing inhibition of degranulation. The anti-degranulation activity and toxicity to mouse RAW264.7 macrophage cells, fatty acid amide hydrolase (FAAH) inhibitory activity, and acetylcholinesterase (AChE) inhibitory activities were evaluated.

RAW264.7 cells are a murine macrophage cell line widely used as a standard model for screening anti-inflammatory properties of natural products. NO is an indicator of the inflammatory response and is synthesized by three types of NO synthases (endothelial, neuronal, and inducible NOS); during inflammation, increased levels of NO produced by iNOS have an important pathological role in many inflammatory diseases. The specific downstream mechanism by which nemophiloside 6 regulates NO in this cell model was not characterized in the published study.

Metalloanthocyanin Color Chemistry (Not a Health Mechanism)

The detailed characterization of nemophilin's formation — involving intramolecular copigmentation between petunidin-based anthocyanins and apigenin-based flavones, stabilized by chelation with Mg²⁺ and Fe³⁺ ions — is well characterized in the scientific literature, but this work pertains exclusively to floral pigmentation chemistry. Anthocyanins localize in the vacuole and are therefore affected by vacuolar pH; alkaline conditions in the vacuole produce bluer colors, and metal ions such as Fe³⁺ and Al³⁺ also enhance blue coloration. No health-relevant mechanisms have been attributed to nemophilin itself in the primary literature.

Scientific Evidence by Area of Use

Anti-Inflammatory Activity

Evidence level: Preliminary; in vitro only.

The sole direct scientific evidence for a potential bioactive effect of an N. menziesii-derived compound on inflammation derives from the 2025 Kurosawa et al. study (PMC12847176). In this in vitro experiment, nemophiloside 6 — one of nine novel meroterpenoid glucosides isolated from whole-plant extract — was tested on LPS-stimulated RAW264.7 murine macrophages. Compound 6 significantly regulated nitric oxide (NO) production from the LPS-stimulated RAW264.7 cells at 100 µg/mL with no toxicity, showing inhibition of degranulation.

This finding is highly preliminary. It is a single study conducted in a cell culture (in vitro) model, not in animals or humans. No dose–response characterization, mechanistic pathway identification, or pharmacokinetic data were reported. No peer-reviewed replications of this finding exist. The result cannot be used to infer any clinical anti-inflammatory benefit in humans.

Cholinesterase and FAAH Inhibition

Evidence level: Negative; in vitro only.

Although the nemophilosides showed little or no inhibitory activity against fatty acid amide hydrolase and acetylcholinesterase, compound 6 regulated NO production in RAW264.7 cells. The testing of nemophilosides against FAAH and AChE was motivated by structural similarities of these meroterpenoids to cannabinoids and by known cholinesterase-inhibitory activity observed in meroterpenoids from other plant genera. The negative result for N. menziesii-derived compounds against both FAAH and AChE is itself a documented scientific finding that should temper any speculation about neurological applications.

Cosmetic and Skin Applications

Evidence level: Inferred from family-level data; no species-specific evidence.

Nemophila menziesii is not among the genera highlighted for cosmetic use in the Boraginaceae family. Extracts or individual compounds of Boraginaceae plants are characterized by antioxidant, anti-inflammatory, antiseptic, anti-irritant, antiaging, and photoprotective activities; Boraginaceae products are widespread in the cosmetic industry as ingredients of creams, balms, lotions, gels, shampoos, lipsticks, perfumes, and deodorants. The most valuable for the cosmetic industry are raw materials obtained from the genera Arnebia, Borago, Echium, Lithospermum, Symphytum, and others. Further research should focus on the search for active substances in other plants of the family — a statement that encompasses N. menziesii as a candidate for future investigation, not a confirmed cosmetic ingredient.

Antioxidant Activity

Evidence level: Hypothetical; no species-specific evidence.

No studies have directly assayed antioxidant activity of N. menziesii extracts or isolated compounds in vitro or in vivo. The presence of flavonoids (apigenin, luteolin, quercetin glycosides) in the petals, as identified incidentally during biosynthetic pathway research, is consistent with antioxidant potential in principle — anthocyanins and flavonoids are broadly recognized as antioxidant compound classes. However, quantitative data on the concentrations of these compounds in N. menziesii tissue, and any measured antioxidant capacity of the plant, are absent from the peer-reviewed literature reviewed here.

Body Systems Associated with Research Interest

• Immune/Inflammatory System: The in vitro finding that nemophiloside 6 modulates NO production in LPS-stimulated macrophages (RAW264.7 cells) places this compound, at the earliest exploratory research stage, in the context of innate immune regulation. NO is a key inflammatory signaling molecule, and its modulation by macrophages is relevant to inflammatory disease research. No human or animal study data exist.
• Neurological System: Testing against AChE and FAAH — enzymes relevant to Alzheimer's disease and endocannabinoid signaling, respectively — yielded negative results for the nemophilosides, meaning the compounds did not inhibit these targets to a meaningful degree.
• Pigment and Food Colorant Research: The unique metalloanthocyanin nemophilin has been studied as a model system for understanding how pure blue colors are generated in flowering plants, with interest in potential applications as a natural blue food or cosmetic colorant, though no food-safety data, stability studies in food matrices, or regulatory approvals specific to nemophilin have been identified in the literature surveyed.

Dosage Forms and Reported Dosages

No clinical trials in humans have been conducted with any preparation of Nemophila menziesii. Consequently, no human dosage recommendations, therapeutic dose ranges, or pharmacokinetically characterized dose levels exist.

In the sole in vitro biological activity study identified: compound 6 (nemophiloside 6) significantly regulated nitric oxide production from LPS-stimulated RAW264.7 cells at 100 µg/mL with no toxicity. This is a cell-culture concentration, not a dose for human use, and cannot be extrapolated to a human dose without pharmacokinetic, absorption, distribution, metabolism, and excretion (ADME) studies.

The phytochemical isolation study used an acetone–water (4:1) extract of 116 g of whole plant material subjected to multi-step chromatographic fractionation; this is a laboratory-scale extraction procedure, not a preparation suitable for or intended for human consumption.

Safety Considerations

Absence of Safety Data

No formal toxicological studies — including acute toxicity, subchronic toxicity, genotoxicity, reproductive toxicity, or allergenicity assessments — of Nemophila menziesii extracts or isolated compounds have been published in peer-reviewed literature. There are no established tolerable upper intake levels, no adverse event reports in clinical databases, and no regulatory assessments from bodies such as EFSA, the FDA, or the EMA pertaining to N. menziesii as a food ingredient, dietary supplement, or herbal medicine.

Pyrrolizidine Alkaloid Concern (Family-Level)

A relevant safety consideration at the family level is the presence of hepatotoxic pyrrolizidine alkaloids (PAs) in certain Boraginaceae genera. Pyrrolizidine alkaloids with toxic properties are found in the family Boraginaceae — mainly in Symphytum spp. — and therefore their applications should be avoided. Whether PAs are present in N. menziesii has not been investigated in the published literature; no targeted PA screening of this species has been reported. This does not confirm absence, and the question remains open for toxicological investigation.

Novel Compound Class

The meroterpenoid glucosides (nemophilosides A–I) described in the 2025 Kurosawa et al. study are previously undescribed compounds. As novel natural products, their safety profiles — including metabolism in humans, potential toxicity at higher doses, interactions with drug-metabolizing enzymes, and possible allergenic properties — are entirely unknown. The in vitro cytotoxicity assessment reported by the study noted no toxicity of nemophiloside 6 at 100 µg/mL in the RAW264.7 cell line, but this is not equivalent to a safety determination for human use.

Invasiveness Classification

In jurisdictions outside its native range, N. menziesii may be classified as a risk species. Assessments such as the Hawaii directory of plant risk ratings have assigned a risk score to the species, reflecting its potential invasiveness in non-native ecosystems, though this is an ecological rather than human-safety concern.

Drug Interactions

No data on drug interactions involving N. menziesii preparations or isolated compounds exist in peer-reviewed literature. Given the structural kinship of the nemophilosides with cannabinoids and shikonins — their skeletons are similar to those of cannabinoids and shikonins, suggesting homologous biosynthetic pathways — and noting that cannabinoids are known inhibitors of cytochrome P450 enzymes involved in drug metabolism, potential interactions would be a logical focus for future preclinical safety research. This remains entirely speculative in the absence of empirical data.

Summary Assessment of Evidence

Nemophila menziesii is primarily an ornamental wildflower native to western North America. Its characterization as a "dietary supplement" or "natural health ingredient" is not supported by the current scientific or regulatory literature. The plant has yielded chemically interesting compounds — most notably the unique metalloanthocyanin nemophilin and a series of novel meroterpenoid glucosides (nemophilosides A–I) discovered in 2025 — but the biological evidence for any of these compounds consists solely of a single in vitro study showing that one compound (nemophiloside 6) modulates NO production in murine macrophage cells at a concentration of 100 µg/mL. No animal studies, no human pharmacokinetic studies, and no clinical trials exist for any preparation or constituent of this plant. Traditional use documentation is extremely limited and does not substantiate specific medicinal applications. The compound class identified is novel, and its safety has not been characterized. The plant's standing in the dietary supplement or herbal medicine field is entirely preliminary at the research stage.

References

• Kurosawa N, Ishikawa Y, Katagiri T, et al. Nemophilosides A–I, nine meroterpenoid glucosides isolated from Nemophila menziesii. Journal of Natural Medicines, 2025. PMC12847176
• Kurosawa N et al. Nemophilosides A–I, nine meroterpenoid glucosides isolated from Nemophila menziesii. J Nat Med (2025). Springer Nature
• Yoshida K, Tojo K, Mori M, et al. Chemical mechanism of petal color development of Nemophila menziesii by a metalloanthocyanin, nemophilin. Tetrahedron, 2015. ScienceDirect
• Noda N et al. Identification and Characterization of Novel Nemophila menziesii Flavone Glucosyltransferases that Catalyze Biosynthesis of Flavone 7,4′-O-Diglucoside, a Key Component of Blue Metalloanthocyanins. Plant and Cell Physiology, 2018. Oxford Academic
• Noda N et al. Identification and Characterization of Novel Nemophila menziesii Flavone Glucosyltransferases. Plant Cell Physiol. 2018. PubMed
• Ono E et al. Molecular cloning of flavonoid biosynthetic genes and biochemical characterization of anthocyanin O-methyltransferase of Nemophila menziesii Hook. and Arn. PMC6543731
• Nemophila menziesii. Wikipedia
• Nemophila menziesii — Plant Finder. Missouri Botanical Garden
• Nemophila menziesii var. menziesii. Plants of the World Online. Kew Science
• Matkowski A et al. Metabolites Obtained from Boraginaceae Plants as Potential Cosmetic Ingredients—A Review. Molecules, 2024. MDPI
• Matkowski A et al. Metabolites Obtained from Boraginaceae Plants as Potential Cosmetic Ingredients—A Review. PMC11547297
• Biological activities of meroterpenoids isolated from different sources. PMC9527340
• Baby Blue Eyes — Plant of the Month. Santa Monica Mountains Trails Council
• Nemophila menziesii. Jepson Herbarium eFlora, University of California